Company Analysis Aarey Drugs & Pharmaceuticals Limited
1. Summary
Advantages
- Current debt level 0% is below 100% and has decreased over 5 years from 1.91%.
Disadvantages
- Price (70.84 βΉ) is higher than fair price (66.05 βΉ)
- Dividends (0%) are below the sector average (0.2278%).
- The stock's return over the last year (33.03%) is lower than the sector average (48.12%).
- The company's current efficiency (ROE=0%) is lower than the sector average (ROE=17.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Aarey Drugs & Pharmaceuticals Limited | Index | ||
|---|---|---|---|
| 7 days | 3.7% | -1.9% | -0.3% |
| 90 days | 52.7% | -1.4% | -7.1% |
| 1 year | 33% | 48.1% | 8.1% |
AAREYDRUGS vs Sector: Aarey Drugs & Pharmaceuticals Limited has significantly underperformed the "" sector by -15.09% over the past year.
AAREYDRUGS vs Market: Aarey Drugs & Pharmaceuticals Limited has outperformed the market by 24.97% over the past year.
Stable price: AAREYDRUGS is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.
Long period: AAREYDRUGS with weekly volatility of 0.6352% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (70.84 βΉ) is higher than the fair price (66.05 βΉ).
Price is higher than fair: The current price (70.84 βΉ) is 6.8% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (14.68).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (65.67).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0) is lower than that of the sector as a whole (2.31).
P/BV vs Market: The company's P/BV (0) is lower than that of the market as a whole (6.56).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (0.8445).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (18.87).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (8.55).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (25.21).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -20% over the last 5 years.
Earnings Slowdown: The last year's return (-100%) is below the 5-year average return (-20%).
Profitability vs Sector: The return for the last year (-100%) is lower than the return for the sector (-1.62%).
5.4. ROE
ROE vs Sector: The company's ROE (0%) is lower than that of the sector as a whole (17.24%).
ROE vs Market: The company's ROE (0%) is lower than that of the market as a whole (3.38%).
5.5. ROA
ROA vs Sector: The company's ROA (0%) is lower than that of the sector as a whole (8.43%).
ROA vs Market: The company's ROA (0%) is lower than that of the market as a whole (7.93%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (17.29%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (15.54%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.2278%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
